Christina Cherny, OD
Corneal and Contact Management · New York, NYNPI 1073188322
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (59.3%), food and beverage and entertainment — rather than concentrated in one kind of arrangement. Valley Contax, Inc. accounts for 77.7% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2022 at $4,212 and has fallen 92.1% since, to $334 in 2025.
Across 37 payments — averaging $138.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Valley Contax, Inc.$4K
- Bausch & Lomb Americas Inc.$265
- Oyster Point Pharma, Inc.$246
- Alcon$201
- Johnson & Johnson Vision Care, Inc.$125
- Sun Pharmaceutical Industries Inc.$118
- plus $188 from 3 others
What the payments were for
- Travel & lodging$3,03259%
- Food & beverage$2,04240%
- Entertainment$381%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Valley Contax, Inc. | 3 | $3,970 |
| Bausch & Lomb Americas Inc. | 7 | $265 |
| Oyster Point Pharma, Inc. | 11 | $246 |
| Alcon | 4 | $201 |
| Johnson & Johnson Vision Care, Inc. | 1 | $125 |
| Sun Pharmaceutical Industries Inc. | 5 | $118 |
| Coopervision Inc. | 3 | $93 |
| Mallinckrodt Hospital Products Inc. | 2 | $71 |
| Thea Pharma Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALDEN SCLERAL ZENLENS$142
- Acuvue$125
- TRYPTYR$125
How this compares
$5,112 in reported general payments places this provider in the 85th percentile of 68 corneal and contact management providers in New York.
See all corneal and contact management providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 48 | $1,886 |
| Ketorolac Tromethamine | 36 | $702 |
| Ofloxacin | 25 | $369 |
| Latanoprost | 26 | $139 |
Paid to pharmacies, not to this prescriber.
Other corneal and contact management in New York
- Kevin RosinNew York$59K
- Kevork NiksarliNew York$27K
- Nadine EisenbergNew York$4K
- Traci GoldsteinNew York$4K
- Ralph GundelNew York$3K
- James SinowayNew York$3K
- Jennifer leNew York$3K
- Cynthia ZaraNew York$2K
- Frederic NevinsNew York$1K
- Melissa Lee KungNew York$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.